TScan Therapeutics' positive earnings report, beating EPS estimates by 28% and showing a notable revenue increase, is likely to instill investor confidence and potentially lead to a short-term stock price increase. Historical data shows that past earnings beats were followed by share price increases, suggesting a similar outcome could be expected.